RAC - Charts & Price Action, page-14691

I think this will change when RACE release and publicly promote the commercial cardioprotection market study they have undertaken in the US.

This will give the likes of DCB & Danny Sharp some tangible market data on the size of cardio protect opportunity in N.America when engaging with BP, institutional and sophisticated investors. I recall Phil also saying they can extrapolate that data to put some estimates around the total global market opportunity for RACE based on the US numbers.

As i've said previously, I think the cardio protect is a simpler investment proposition for investors to wrap their heads around compared to FTO. Leveraging this primary market data from the US, I think this will underpin RACE's value proposition when it begins marketing to a global audience this year.

the interim, I will continue to accumulate whilst I can at these levels.